Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 15;13:899971. doi: 10.3389/fimmu.2022.899971

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Cheng, Wang, Hu, Sun, Zhao, Zhang, Wang, Wang and Xiong

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) On April 29, 2020, chest computed tomography (CT) before chemotherapy showed mild ground glass opacity in the lower lobe of the right lung. (B) On December 1, 2020, after 6 months of tislelizumab treatment, chest CT showed diffuse ground glass and solid opacity in both lungs, more severe in both lower lungs. (C) On December 24, 2020, after 3 weeks of prednisone treatment, chest CT showed pulmonary infiltration had improved. (D) pulmonary infiltration continued to improve on Feb 19, 2021. (E) Multiple subpleural ground glass lesions recurred in both lungs on May 2, 2021 (The patient received 10 mg prednisone). (F) The patient responded to azathioprine (150 mg per day) on November 19, 2021.